Navigation Links
AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
Date:2/1/2011

CINCINNATI, Feb. 1, 2011 /PRNewswire/ -- AssureRx Health, Inc. today announced the appointments of two senior executives in key roles to drive company growth. Donald R. Wright, Jr. has been appointed as executive vice president & chief operating officer and John A. Bellano as senior vice president, sales & commercial programs.

Wright has been instrumental in leading the development of AssureRx's pharmacogenetic test, GeneSightRx®, and the blueprint of products the company expects to develop over the next two to three years. In his new position, Wright will play a fundamental role in leading AssureRx's future product offerings, operations, and external relationships and he will continue managing software product development, overseeing information technology and molecular genetics laboratory operations, as well as customer support, field sales support, quality assurance, and human resources. Wright brings over 20 years of software product development and operations expertise, including Attachmate where he led a 700 member software team and the creation and support of a $450 million software product line. Wright also served as chief technology officer and chief information officer in various software companies and has participated in more than 25 successful product launches.

Bellano is joining AssureRx as a key member of the executive team, leading the company's sales efforts to increase adoption of GeneSightRx, launching new products in development, and leading the company's efforts with Diamond Healthcare and other strategic partners. Bellano also brings 20 years of experience to AssureRx, most recently as senior vice president, commercial operations for GenMark, a molecular diagnostics company, and as vice president, sales for Hologic Inc., a developer and manufacturer of women's health care products and systems. Prior to Hologic, Bellano served as vice president, sales for Third Wave, a provider of DNA and RNA products for the clinical and research markets, where he played a key role in building market adoption that led to Third Wave's acquisition by Hologic. Prior to Third Wave, John held various molecular diagnostic sales positions with Roche Diagnostics, Sanofi Diagnostics Pasteur, Abbott Laboratories and Forest Laboratories.

"Our goal is to build the leading medical informatics company providing pharmacogenetic and other clinical decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders," said James S. Burns, president & CEO of AssureRx. "Strengthening the leadership team is an important step for AssureRx this year as we build sales momentum and launch our second product. Don and John have the leadership skills and experience to meet our customers' needs for treatment support products that can help improve patient care at substantially reduced costs."

About AssureRx HealthAssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and other treatment decision support products to help physicians determine the right drug and the right dose for individual patients suffering from neuropsychiatric disorders. The company was founded in 2006 to commercialize industry-leading personalized medicine technology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators.

About GeneSightRx®

GeneSightRx® is a laboratory developed genetic test that uses leading edge technology to measure and analyze clinically important genetic variants that affect how individuals metabolize psychiatric medicine. The test results can help a doctor understand the way a patient's unique genetic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, incorporating FDA approved manufacturers' drug labels, peer-reviewed scientific publications, and proven pharmacology. Quick turnaround time, combined with a customized report of the patient's genetic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenetics and GeneSightRx, please click here. Be sure to watch the educational video.Contacts:James S. BurnsPresident & CEOAssureRx Health, Inc.Tel: (513) 234-0510e-mail: jburns@assurerxhealth.comAndreas Marathovouniotis or David Schull Russo PartnersTel: (212) 845-4235 or (212) 845-4271e-mail: andreas.marathis@russopartnersllc.com or david.schull@russopartnersllc.com
'/>"/>

SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic Appoints Mark D. Myslinski as Senior Vice President and General Manager of Diagnostics
2. Sysmex America Appoints Vice President of Sales
3. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
4. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
5. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
6. Interventional Spine®, Inc. Appoints Stephen Colaiezzi, Senior Vice President, Strategic Marketing
7. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
8. Symmetry Medical Board of Directors Appoints Thomas J. Sullivan President and Chief Executive Officer
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
11. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/28/2017)... Salt Lake City, UT (PRWEB) , ... April 28, 2017 , ... ... that exist in some of their formulas. This begins with the popular ClearLungs Extra ... impacted, they will be changing the formula in the following ways:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to ... of Water, Global Climate Change and Your Health on Voice America sponsored by ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
(Date:4/28/2017)... ... , ... People are starting to accept that hearing aids can be helpful ... stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer ... East region. Côté has 20+ years of experience within the beauty industry, ranging ... with an array of high-end cosmetic brands, retail brands and outlets in Canada ...
Breaking Medicine News(10 mins):